Valneva SE (VALN) Long-Term Deferred Tax (2020 - 2026)
Valneva SE (VALN) posted quarterly Long-Term Deferred Tax of $8.8 million for Q1 2026, down 2.27% year-on-year from $9.0 million in Q1 2025, and down 6.81% on a QoQ basis from $9.5 million in Q4 2025.
Valneva SE (VALN) Long-Term Deferred Tax (2020 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Long-Term Deferred Tax for 7 consecutive years, with $8.8 million the latest figure, recorded in Q1 2026.
- Quarterly Long-Term Deferred Tax fell 2.27% year-over-year to $8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.8 million (down 2.27% YoY) and the FY2025 annual result came in at $9.5 million, down 13.32% from the prior year.
- Long-Term Deferred Tax retreated to $8.8 million in Q1 2026 per VALN's latest filing, from $9.5 million in the prior quarter.
- Over the last five years, Long-Term Deferred Tax for VALN reached as high as $236.5 million in Q4 2023 and fell as low as $3.0 million in Q2 2022.
- A 5-year average of $21.6 million and a median of $8.8 million in 2026 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2023 — Long-Term Deferred Tax soared 3587.39% — and 2024, when it slumped 95.38%.
- Year by year, Long-Term Deferred Tax stood at $6.4 million in 2022, then surged by 3587.39% to $236.5 million in 2023, then sank by 95.38% to $10.9 million in 2024, then retreated by 13.32% to $9.5 million in 2025, then fell by 6.81% to $8.8 million in 2026.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $8.8 million, $9.5 million, and $8.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.83 Mn |
| Dec 31, 2025 | 9.47 Mn |
| Sep 30, 2025 | 8.35 Mn |
| Jun 30, 2025 | 9.11 Mn |
| Mar 31, 2025 | 9.03 Mn |
| Dec 31, 2024 | 10.93 Mn |
| Sep 30, 2024 | 13.28 Mn |
| Jun 30, 2024 | 8.72 Mn |
| Mar 31, 2024 | 7.97 Mn |
| Dec 31, 2023 | 236.53 Mn |
| Sep 30, 2023 | 10.46 Mn |
| Jun 30, 2023 | 11.30 Mn |
| Mar 31, 2023 | 6.99 Mn |
| Dec 31, 2022 | 6.41 Mn |
| Sep 30, 2022 | 3.35 Mn |
| Jun 30, 2022 | 3.05 Mn |
| Mar 31, 2022 | 3.76 Mn |
| Dec 31, 2021 | 4.08 Mn |
| Dec 31, 2020 | 6.34 Mn |